Evidence map›Paper›PMID 37249415›Full record

ArticlePediatric blood & cancer2023

Humoral profiling of pediatric patients with cancer reveals robust immunity following anti-SARS-CoV-2 vaccination superior to natural infection.

Samantha D Martin, Nadège Nziza, Pietro Miozzo, Yannic Bartsch, Eva J Farkas, Abigail S Kane, Lauren H Boal, Alison Friedmann, Galit Alter, Lael M Yonker

Open access · greenAbstract read
In one paragraph

Article in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Samantha D MartinDepartment of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0009-0007-0516-3975
Nadège NzizaRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT), and Harvard, Boston, Massachusetts, USA.
Pietro MiozzoDepartment of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
Yannic BartschRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT), and Harvard, Boston, Massachusetts, USA.
Eva J FarkasDepartment of Pediatrics, Pulmonary Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
Abigail S KaneDepartment of Pediatrics, Pulmonary Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
Lauren H BoalDepartment of Pediatrics, Hematology/Oncology Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
Alison FriedmannDepartment of Pediatrics, Hematology/Oncology Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
Galit AlterRagon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT), and Harvard, Boston, Massachusetts, USA.
Lael M YonkerDepartment of Pediatrics, Pulmonary Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
Massachusetts General Hospital · USRagon Institute of MGH, MIT and Harvard · US

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Laura D. Hughes · 2018 to 2026
$32.0M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
SARS-CoV-2 Variant TestingR01AI146785 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2020 to 2024
$3.3M
Defining neutrophil pathobiology in pediatric Long COVIDR01HL173059 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Lael Yonker · 2024 to 2026
$2.4M
CHLAMYDIA PNEUMONIAE AND MACROPHAGES IN ATHEROSCLEROSISR01AI042790 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI BYRNE, GERALD IRWIN · 1999 to 2003
$983k
Mechanistically Disentangling the Infected, Inflamed LungK08HL143183 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YONKER, LAEL · 2018 to 2022
$869k
NCI NIH HHS U01 CA260476NHLBI NIH HHS K08 HL143183NHLBI NIH HHS R01 HL173059NIAID NIH HHS 75N93019C00052NIAID NIH HHS R01 AI042790NIAID NIH HHS R01 AI146785NIAID NIH HHS R37 AI080289NIAID NIH HHS U19 AI135995NIH HHS 1U01CA260476-01NIH HHS 3R37AI080289-11S1NIH HHS 5K08HL143183NIH HHS CIVIC75N93019C00052NIH HHS R01AI146785NIH HHS U19AI135995-02NIH HHS U19AI42790-01
6 · The paper itself

Abstract

backgroundPediatric patients with cancer infected with COVID-19 may be at higher risk of severe disease and may be unable to mount an adequate response to the virus due to compromised immunity secondary to their cancer therapy. PROCEDURE: This study presents immunologic analyses of 20 pediatric patients with cancer, on active chemotherapy or having previously received chemotherapy, and measures their immunoglobulin titers and activation of cellular immunity response to acute SARS-CoV-2 infection and COVID-19 vaccination compared with healthy pediatric controls.

resultsForty-three patients were enrolled, of which 10 were actively receiving chemotherapy, 10 had previously received chemotherapy, and 23 were healthy controls. Pediatric patients with cancer had similar immunoglobulin titers, antibody binding capacity, and effector function assay activity after vaccination against COVID-19 compared with healthy controls, though more variability in response was noted in the cohort actively receiving chemotherapy. Compared with acute infection, vaccination against COVID-19 produced superior immunoglobulin responses, particularly IgA1, IgG1, and IgG3, and elicited superior binding capacity and effector function in children with cancer and healthy controls.

conclusionsPediatric patients receiving chemotherapy and those who had previously received chemotherapy had adequate immune activation after both vaccination and acute infection compared to healthy pediatric controls, although there was a demonstrated variability in response for the patients on active chemotherapy. Vaccination against COVID-19 produced superior immune responses compared to acute SARS-CoV-2 infection in pediatric patients with cancer and healthy children, underscoring the importance of vaccination even in previously infected individuals.

Indexed as

COVID-19NeoplasmsAntibodies, ViralChildCOVID-19 VaccinesHumansImmunity, HumoralImmunoglobulin AImmunoglobulin GSARS-CoV-2VaccinationAntibodies, ViralCOVID-19 VaccinesImmunoglobulin AImmunoglobulin GcancercoronavirusCOVID-19immunityimmunosuppressedvaccination

Identifiers

PMID37249415
PMCPMC10321888
OpenAlexW4378744896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.